Literature DB >> 19930182

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.

Giovanni Barosi, Gunnar Birgegard, Guido Finazzi, Martin Griesshammer, Claire Harrison, Hans Hasselbalch, Jean-Jacques Kiladijan, Eva Lengfelder, Ruben Mesa, Mary F Mc Mullin, Francesco Passamonti, John T Reilly, Alessandro M Vannucchi, Tiziano Barbui.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19930182     DOI： 10.1111/j.1365-2141.2009.08019.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  41 in total

1.  Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2014-10

2.  Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.

Authors:  Kathleen Jentsch-Ullrich; Judith Eberhardt; Vanja Zeremski; Michael Koehler; Denise Wolleschak; Florian H Heidel
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-18       Impact factor: 4.553

3.  The European LeukemiaNet: achievements and perspectives.

Authors:  Rüdiger Hehlmann; David Grimwade; Bengt Simonsson; Jane Apperley; Michele Baccarani; Tiziano Barbui; Giovanni Barosi; Renato Bassan; Marie C Béné; Ute Berger; Thomas Büchner; Alan Burnett; Nicolas C P Cross; Theo J M de Witte; Hartmut Döhner; Hervé Dombret; Hermann Einsele; Georg Engelich; Robin Foà; Christa Fonatsch; Nicola Gökbuget; Elaine Gluckman; Alois Gratwohl; Francois Guilhot; Claudia Haferlach; Thorsten Haferlach; Michael Hallek; Jörg Hasford; Andreas Hochhaus; Dieter Hoelzer; Jean-Jaques Kiladjian; Boris Labar; Per Ljungman; Ulrich Mansmann; Dietger Niederwieser; Gert Ossenkoppele; José M Ribera; Harald Rieder; Hubert Serve; Petra Schrotz-King; Miguel A Sanz; Susanne Saussele
Journal:  Haematologica       Date:  2010-11-03       Impact factor: 9.941

4.  Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.

Authors:  Keita Kirito; Kenshi Suzuki; Koichi Miyamura; Masahiro Takeuchi; Hiroshi Handa; Shinichiro Okamoto; Brian Gadbaw; Kyosuke Yamauchi; Taro Amagasaki; Kazuo Ito; Masayuki Hino
Journal:  Int J Hematol       Date:  2017-09-27       Impact factor: 2.490

5.  Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Authors:  Srdan Verstovsek; Alessandro M Vannucchi; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Keita Kirito; Carlos Besses; Masayuki Hino; Beatriz Moiraghi; Carole B Miller; Mario Cazzola; Vittorio Rosti; Igor Blau; Ruben Mesa; Mark M Jones; Huiling Zhen; Jingjin Li; Nathalie Francillard; Dany Habr; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2016-04-21       Impact factor: 9.941

Review 6.  Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Expert Opin Investig Drugs       Date:  2016-10-31       Impact factor: 6.206

Review 7.  JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Blood       Date:  2017-05-12       Impact factor: 22.113

Review 8.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

9.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

Review 10.  Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.

Authors:  Matjaz Sever; Kate J Newberry; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2014-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.